Illumina (NASDAQ:ILMN)‘s stock had its “hold” rating restated by investment analysts at BTIG Research in a note issued to investors on Tuesday.
A number of other equities analysts also recently issued reports on the stock. Piper Jaffray Companies reiterated an “overweight” rating and issued a $226.00 price target (up previously from $202.00) on shares of Illumina in a report on Monday, October 9th. Wells Fargo & Co upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 price target for the company in a report on Tuesday, January 2nd. Morgan Stanley increased their price target on shares of Illumina from $122.00 to $135.00 and gave the company an “underweight” rating in a report on Thursday, December 14th. Citigroup increased their price target on shares of Illumina from $180.00 to $220.00 and gave the company a “neutral” rating in a report on Wednesday, October 25th. Finally, Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the stock. Illumina has a consensus rating of “Buy” and an average price target of $220.13.
Illumina (NASDAQ:ILMN) opened at $241.42 on Tuesday. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41. The stock has a market cap of $35,250.00, a PE ratio of 45.55, a PEG ratio of 3.30 and a beta of 0.79. Illumina has a twelve month low of $156.50 and a twelve month high of $248.97.
In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $207.88, for a total transaction of $334,478.92. Following the sale, the senior vice president now directly owns 7,217 shares of the company’s stock, valued at approximately $1,500,269.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Epstein sold 1,250 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $226.55, for a total transaction of $283,187.50. Following the sale, the director now directly owns 9,088 shares in the company, valued at $2,058,886.40. The disclosure for this sale can be found here. Insiders have sold a total of 137,671 shares of company stock worth $29,485,768 over the last ninety days. 0.89% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the business. Federated Investors Inc. PA boosted its position in shares of Illumina by 46.2% in the second quarter. Federated Investors Inc. PA now owns 3,704 shares of the life sciences company’s stock worth $642,000 after acquiring an additional 1,171 shares during the last quarter. Neuberger Berman Group LLC boosted its position in shares of Illumina by 35.7% in the second quarter. Neuberger Berman Group LLC now owns 4,893 shares of the life sciences company’s stock worth $849,000 after acquiring an additional 1,286 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Illumina in the second quarter worth approximately $226,000. Riverhead Capital Management LLC boosted its position in shares of Illumina by 20.7% in the second quarter. Riverhead Capital Management LLC now owns 2,313 shares of the life sciences company’s stock worth $401,000 after acquiring an additional 397 shares during the last quarter. Finally, Nationwide Fund Advisors boosted its position in shares of Illumina by 9.6% in the second quarter. Nationwide Fund Advisors now owns 101,545 shares of the life sciences company’s stock worth $17,620,000 after acquiring an additional 8,895 shares during the last quarter. 91.60% of the stock is currently owned by institutional investors.
Illumina Company Profile
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.